We investigated the role of ET-1 axis in CLL setting evaluating the possibility to interfere with these signals by using macitentan, a novel potent dual ETA/ETB receptor antagonist. This evidence concerns the gene EDNRA and B-cell chronic lymphocytic leukemia.